Truist raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $230 from $220 and keeps a Buy rating on the shares. The firm cites the company’s “practice-changing data” from HERIZON-GEA presented last week at ASCO GI that justifies its upward revision of Ziihera estimates, the analyst tells investors in a research note. Truist adds that it sees further upside from this pipeline-in-a-drug opportunity, particularly in breast cancer and other solid tumors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals price target raised to $235 from $210 at Needham
- BofA ups Jazz Pharmaceuticals price target, says selloff ‘unwarranted’
- Closing Bell Movers: AXT Inc. slips after cutting Q4 revenue guidance
- Jazz Pharmaceuticals names Thomas Riga as Chief Business Officer
- Jazz Pharmaceuticals price target raised to $225 from $205 at Morgan Stanley